0.10 | 1.33%
- Employers: Entry-Level Applicants Are Just About Useless
- Walmart vs. Costco: How Do They Really Compare?
- Tesla Pops on GM Rumor (Update 1)
- Putting a Fingerprint on Every Bullet
- Why Apple Sucks as an Investment, but Amazon Doesn't
|
|
|
|
|
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 7.51 |
| 52 Week High | 13.50 |
| 52 Week Low | 6.95 |
| Avg. Daily Vol. (Mil) | 5.43 |
| Beta (3 year) | -0.86 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,635.51 |
| Shares Out (Mil) | 217.78 |
| Float (Mil) | 216.55 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.10 |
| Current Ratio | 5.50 |
| LT Debt/ Equity | 0.90 |
| Total Debt / Equity | 0.92 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 58.89 |
| Price/Book | 20.34 |
| Price/Cash Flow | -24.40 |
| Per Share Data | |
| Earnings | -0.38 |
| Sales | 0.13 |
| Book Value | 0.37 |
| Cash Flow | -0.31 |
| Business Summary | |
|---|---|
| Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases. | |
| General Information | |
| 6154 Nancy Ridge Drive
San Diego, CA 92121 |
|
| www.arenapharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 293 | |
| CEO: Jack Lief | |
| Short Interest | |
| Current Month (Mil) | 57.32 |
| Previous Month (Mil) | 59.55 |
| Short Interest Ratio (Days) | 8.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -32.90 |
| Return on Investments | -50.00 |
| Profitability | |
| Gross Margin | 82.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
|
|
Brokerage Partners
|
|
|
|
|
|
|
|
Most Commented
Advertising Partners
|
|
|
|
We respect your privacy.